RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS
Mikito Shimizu, Naoyuki Shiraishi, Satoru Tada, Tsutomu Sasaki, Goichi Beck, Seiichi Nagano, Makoto Kinoshita, Hisae Sumi, Tomoyuki Sugimoto, Yoko Ishida, Toru Koda, Teruyuki Ishikura, Yasuko Sugiyama, Keigo Kihara, Minami Kanakura, T. Nakajima, Shuko Takeda, Masanori Takahashi, Toshihide Yamashita, Tatsusada Okuno, Hideki Mochizuki
Abstract
Repulsive guidance molecule A (RGMa) was originally identified as a neuronal growth cone-collapsing factor. Previous reports have demonstrated the multifunctional roles of RGMa mediated by neogenin1. However, the pathogenic involvement of RGMa in amyotrophic lateral sclerosis (ALS) remains unclear. Here, we demonstrated that RGMa concentration was elevated in the cerebrospinal fluid of both patients with ALS and transgenic mice overexpressing the mutant human superoxide dismutase1 (mSOD1 mice). Treatment with humanized anti-RGMa monoclonal antibody ameliorated the clinical symptoms in mSOD1 mice. Histochemical analysis revealed that the anti-RGMa antibody significantly decreased mutant SOD1 protein accumulation in the motor neurons of mSOD1 mice via inhibition of actin depolymerization. In vitro analysis revealed that the anti-RGMa antibody inhibited the cellular uptake of the mutant SOD1 protein, presumably by reinforcing the neuronal actin barrier. Collectively, these data suggest that RGMa leads to the collapse of the neuronal actin barrier and promotes aberrant protein deposition, resulting in exacerbation of the ALS pathology.